For Research Use Only

CJC-1295 (No DAC) and Ipamorelin are two synthetic research peptides often studied in
combination for their complementary roles in stimulating endogenous growth hormone (GH)
secretion. When used together in research settings, these peptides are believed to enhance
GH release through distinct but synergistic pathways, making them of particular interest in
studies of growth hormone regulation and metabolic function.

What Are They?
• CJC-1295 (No DAC): A short-acting analog of growth hormone-releasing hormone
(GHRH), composed of the first 29 amino acids of native GHRH. It is known for supporting a
pulsatile GH release pattern, which closely mirrors the body’s natural secretion rhythms.
• Ipamorelin: A selective ghrelin receptor agonist (GHS) that promotes GH release without
significantly affecting levels of cortisol, prolactin, or appetite in research models. It’s noted
for its targeted action and favorable receptor selectivity.

Mechanism of Interest (Based on Research)
• CJC-1295 (No DAC): Binds to GHRH receptors on the anterior pituitary, triggering a GH
response that mimics physiological pulsatility.
• Ipamorelin: Engages the ghrelin receptor (GHS-R1a), promoting GH release via a different
receptor pathway with minimal off-target hormonal activity.

Together, these peptides are researched for their potential to support natural GH secretion
rhythms and enhance the overall amplitude and frequency of GH pulses.

Research Focus Areas
• Endocrine Function and GH Dynamics
• Body Composition Studies
• Muscle Repair and Recovery Modeling
• Sleep and Circadian Rhythm Research

• Aesthetic and Cellular Aging Markers

Observations in Literature
• Combined use is often investigated for GH secretion enhancement
• Explored for roles in metabolic regulation and tissue repair
• Subject of interest in performance optimization model
 

Benefits

• Increased Muscle Mass: Enhanced protein synthesis and muscle growth. 

• Fat Loss: Improved fat metabolism and reduced fat accumulation.

• Improved Recovery: Faster recovery from exercise and injury. 

• Better Sleep Quality: Promotion of deep, restorative sleep. 

• Enhanced Skin Health: Improved skin elasticity and reduced wrinkles. 

• Increased Energy Levels: Boosted overall vitality and well-being.

These benefits make the combination of CJC-1295 (No DAC) and Ipamorelin popular among individuals seeking toenhance their physical performance and overall health. 

CJC-1295 (No DAC) vs. CJC-1295 (With DAC)

• CJC-1295 (No DAC): Has a shorter half-life (~30 minutes), leading to a more natural, pulsatile release of GH. 

• CJC-1295 (With DAC): Contains a drug affinity complex (DAC) that extends its half-life to approximately 6-8 days,providing a sustained release of GH.